Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who have suffered losses in excess of $75,000 from Humacyte to contact him directly to discuss their options.
If you have a loss of more than $75,000 Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson live at the 877-247-4292 or 212-983-9330 (Ext. 1310).
(You can click here for more information)
New York, New York– (Newsfile Corp. – December 28, 2024) – Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”). (NASDAQ: HUMA) and reminds investors January 17, 2025 deadline seeking the role of lead plaintiff in a securities class action filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has received hundreds of millions of dollars from investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or by failing to disclose that: (1) the Company's Durham, North Carolina location was unable to comply with the good product. practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA will be delayed while Humacyte corrects these deficiencies; and (3) that, as a result, there was a significant risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, the Defendants' positive statements regarding the Company's business, operations, and prospects were materially misleading and/or unsubstantiated.
On August 9, 2024, after the market closed, Humacyte issued a press release announcing that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of the Biologic License Application (BLA) for -acellular tissue made. vessel (ATEV) in vascular trauma indication.” The press release disclosed in part, that, “(d)uring the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical facilities and has actively engaged with us in several discussions regarding the filing of our BLA (.)”
On this news, the Company's stock price declined $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024, with unusually heavy volume.
On October 17, 2024, during market hours, the FDA issued a Form 483 regarding Humacyte's Durham, North Carolina location, which revealed a number of violations, including “no microbial quality assurance,” “no microbial testing,” and inadequate “quality control.” .”
On this news, the Company's stock price fell $0.95, or 16.35%, to close at $4.86 per share on October 17, 2024, on unusually heavy volume.
A court-appointed lead plaintiff is an investor with a substantial financial interest in the relief sought by a sufficient and common class of class members who administers and oversees the lawsuit on behalf of the putative class. Any privileged class member may move the Court to act as lead plaintiff through counsel of his or her own choosing, or may choose to remain inactive and remain a non-class member. Your ability to share in any recovery is not affected by the decision to act as the lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information about Humacyte's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Follow us for updates on LinkedIn, X, or Facebook (NASDAQ:).
Marketing Lawyer. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict the same result with respect to any future matter. We welcome the opportunity to discuss your specific situation. All communications will be treated confidentially.
To view the source of this document, please visit https://www.newsfilecorp.com/release/234707